Prognostic Impact of Lymph Node Ratio in Adenocarcinoma of the Esophagogastric Junction: A Retrospective Analysis with Nodal Distribution Patterns


Thammawat Parakonthun, M.D.1,2, Seen Piriyanontana, M.D.1, Chawisa Nampoolsuksan, M.D.1,2,*, Tharathorn Suwatthanarak, M.D., Ph.D.1, Jirawat Swangsri, M.D., Ph.D.1,2, Asada Methasate, M.D., Ph.D.1,2

1Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand, 2Siriraj Upper Gastrointestinal Cancer

Center, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.



*Corresponding author: Chawisa Nampoolsuksan E-mail: chawisa.nam@mahidol.ac.th

Received 16 July 2026 Revised 9 August 2026 Accepted 10 August 2026 ORCID ID: http://orcid.org/0000-0002-5990-4704 https://doi.org/10.33192/smj.v78i11.283704


All material is licensed under terms of the Creative Commons Attribution 4.0 International (CC-BY-NC-ND 4.0) license unless otherwise stated.


ABSTRACT

Objective: To evaluate the prognostic impact of the lymph node ratio (LNR) on survival in patients with adenocarcinoma of the esophagogastric junction (AEG) undergoing curative-intent surgery and to characterize patterns of lymph node distribution according to nodal station and Siewert classification.

Materials and Methods: This retrospective cohort study included patients with AEG who underwent curative-intent esophagogastrectomy at a university hospital between January 2005 and June 2022. Clinicopathological data and survival outcomes were reviewed. LNR was categorized into three groups: LNR=0, 0<LNR<0.2, and LNR≥0.2. Overall survival was analyzed using the Kaplan–Meier and Cox proportional hazards regression analyses. The distribution of nodal metastasis was evaluated using station-based lymph node mapping.

Results: Sixty-seven patients were included in the final analysis. Most patients presented with advanced-stage disease, and pathological stage III was the most common stage (41.8%). The median number of harvested lymph nodes was 34 (21, 43) nodes. Patients with LNR≥0.2 had the poorest survival outcomes, with a median overall survival of 11 months compared with 36 months for patients with 0<LNR<0.2 and 155 months for those with LNR=0 (p<0.001). On multivariate analysis, LNR≥0.2 (adjusted HR 5.90, 95%CI 2.14–16.25, p=0.001) and R1 resection (adjusted HR 2.78, 95%CI 1.16-6.93, p=0.028) remained independent predictors of poor survival. Lymph node metastases were predominantly distributed within the perigastric and celiac-axis stations.

Conclusion: Higher LNR was associated with poorer overall survival after curative-intent surgery for AEG. Given the single-center cohort and data-derived cut-off, future validation should be conducted.

Keywords: Adenocarcinoma; esophagogastric junction; lymph node ratio; lymph node mapping (Siriraj Med J 2026;78(11):836-846)


INTRODUCTION

Adenocarcinoma of the esophagogastric junction (AEG) is a malignancy arising at the transition between the distal esophagus and proximal stomach. Owing to its unique anatomical location, pattern of lymphatic spread, and distinct biological behavior, AEG is considered to be a separate disease entity from both distal gastric cancer and esophageal adenocarcinoma.1 In recent decades, the incidence of AEG has steadily increased worldwide, particularly in Western countries, and a similar rising trend has also been observed in Asian populations.2,3 This has generated increasing clinical interest in optimizing the management and prognostic assessment of the disease. Siewert and Stein classified AEG into types I–III according to the location of the tumor epicenter relative to the esophagogastric junction (EGJ).4 This classification remains clinically important because it guides the operative approach, determines the balance between esophageal and gastric resection, and influences the extent of mediastinal and abdominal lymphadenectomy.5,6 In addition to the Siewert classification, lymph node status remains one of the most important prognostic determinants in patients with AEG. Previous studies from China and Japan have demonstrated patterns of nodal metastasis, demonstrating that the optimal extent and distribution of lymphadenectomy may differ

according to tumor location and Siewert subtype.7,8 The presence of lymph node metastasis is strongly associated with perioperative treatment strategies, recurrence, and long-term survival.9,10 Currently, the American Joint Committee on Cancer (AJCC) staging system classifies nodal disease according to the number of metastatic nodes and is widely used for prognostic stratification and treatment planning.11 Accurate nodal staging requires adequate lymphadenectomy and pathological evaluation.12 Current guidelines generally recommend the retrieval of at least 16 lymph nodes to ensure reliable assessment.13 However, adequate lymph node harvest may not always be achievable in some situations. The technical complexity of surgery at EGJ can contribute to insufficient nodal retrieval. Furthermore, in patients who receive preoperative treatment, lymph node regression and treatment-related fibrosis may reduce the number of identifiable lymph nodes, potentially resulting in understaging despite appropriate oncologic surgery.

To overcome this limitation, the lymph node ratio (LNR), defined as the ratio of metastatic lymph nodes to the total number of examined lymph nodes, has been proposed as an alternative parameter. Several studies have demonstrated that LNR may provide more stable prognostic discrimination than conventional nodal staging, particularly in patients with limited lymph node harvest

or those who have undergone neoadjuvant treatment.14,15 Previous meta-analyses of esophageal cancer, including both squamous cell carcinoma and adenocarcinoma, have demonstrated a significant association between a high LNR and poorer survival outcomes.16,17 Similarly, studies in gastric cancer have consistently reported that increasing LNR is strongly correlated with worse overall survival, higher recurrence rates, and more aggressive tumor behavior.18,19 This prognostic significance has also been observed in patients with locally advanced disease who received neoadjuvant therapy, despite the potential effects of chemotherapy on lymph node yield and pathological downstaging.20 These findings further support the role of LNR as a robust prognostic indicator regardless of tumor location or histologic subtype.

However, evidence regarding the prognostic role of LNR in Southeast Asian populations remains limited, and the optimal LNR cut-off value for AEG varies across published studies. In Thailand, gastric cancer remains a significant health burden, and a previous study in gastric cancer demonstrated that an LNR cut-off value of 0.2 was strongly associated with recurrence and provided meaningful prognostic stratification.21 Nevertheless, AEG is not separately classified in the national cancer registry, resulting in limited disease-specific regional data regarding prognostic factors and the distribution patterns of metastatic lymph node stations. This highlights the need for further studies to clarify the prognostic significance of LNR in AEG and to support more accurate risk stratification and treatment planning in regional clinical practice. Furthermore, most available evidence regarding the prognostic value of LNR in AEG has been derived from populations outside Southeast Asia, while regional data remain scarce. Evaluating LNR in a Thai cohort may therefore provide complementary regional evidence and help determine whether previously reported prognostic associations are also observed in this underrepresented population.

Therefore, this study aimed to evaluate the impact of LNR on survival outcomes in patients with AEG undergoing curative-intent surgery and to characterize patterns of lymph node metastasis using station-based mapping of mediastinal and abdominal lymphadenectomy specimens.

MATERIALS AND METHODS

All patients aged 18 years or older with a diagnosis of AEG who underwent curative-intent esophagogastrectomy between January 2005 and June 2022 were consecutively identified from our institutional database. Each patient was included only once. Patients with distant metastasis,

those who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, and those with incomplete pathological data, particularly regarding lymph node status, were excluded. Clinicopathological data were extracted from medical records and operative reports. Demographic characteristics, including age, sex, physical status, tumor characteristics, operative details and pathological findings, were collected.

Following diagnosis and preoperative assessment, esophagogastroscopy was performed to determine the location of the tumor epicenter relative to the esophagogastric junction and classify tumors according to the Siewert classification and contrast-enhanced computed tomography was performed to evaluate lymph node and distant metastasis. Then patients received preoperative treatment according to clinical stage. Neoadjuvant concurrent chemoradiotherapy generally consisted of cisplatin plus 5-fluorouracil (5-FU) with radiotherapy to a total dose of 50.4 Gy, while some patients treated in the later study period received the CROSS regimen. Perioperative chemotherapy regimens included FOLFOX or ECF, with FLOT increasingly used in the later period for patients with adequate performance status. The operative approach, either transthoracic or transabdominal, was selected based on tumor location, lymph node status and disease stage to achieve adequate resection margins and lymphadenectomy. Lymph nodes from the resected specimen were routinely dissected and labeled according to nodal station prior to pathological examination. Tumors were staged according to the 8th edition of American Joint Committee on Cancer staging system. All cases were retrospectively restaged according to this edition. Stage IVa included locally advanced M0 disease, whereas patients with distant metastasis (M1) were excluded from this study. Postoperative surveillance was conducted in accordance with the treatment guidelines. Overall survival was defined as the time from the date of surgery to death from any cause or the last follow-up. Patients who were alive at the time of the last follow-up were censored on the date of their last follow-up.

LNR was calculated as the ratio of metastatic lymph nodes to the total number of harvested lymph nodes. A cut-off value of ratio of 0.2 was selected because it provided the most significant prognostic result for survival within our cohort. Therefore, this should be considered exploratory and data-derived. All patients were categorized into three groups for analysis: LNR=0, 0<LNR<0.2, and LNR≥0.2 for analyses. The study protocol was approved by the Siriraj Institutional Review Board (COA no. Si 522/2022).

Statistical analyses

Descriptive statistics were used to summarize baseline clinicopathological characteristics. Continuous variables were expressed as mean ± standard deviation or median with interquartile ranges, while categorical variables were expressed as number (%). Comparisons between three groups were performed using the one-way ANOVA or Kruskal-Wallis test for continuous variables, and the chi-square or Fisher’s exact test for categorical variables, as appropriate. Overall survival was estimated using the Kaplan–Meier method and compared between subgroups using the log-rank test. Cox proportional hazards regression analysis was performed to estimate hazard ratios (HR) and 95% confidence intervals (CI) for potential prognostic factors. Variables with a p-value<0.10 in univariate analysis or considered clinically relevant were included in a multivariate Cox regression model using forward stepwise selection based on the likelihood ratio test. A two-sided p<0.05 was considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics version 26.


RESULTS

Between January 2005 and June 2022, 199 patients were diagnosed with AEG. Of these, 126 patients presented with distant metastasis, three received palliative treatment, two underwent cytoreductive surgery, and one lacked pathological lymph node data. After applying the exclusion criteria, 67 patients were included in the final analysis. Baseline clinicopathologic characteristics stratified by Siewert subtype are summarized in Table 1. The cohort was predominantly male (67.2%), with a mean age of 64.6 ± 13.5 years. Most patients presented with advanced-stage disease. Pathological T3 and T4 tumors accounted for 30 (44.8%) and 18 (26.9%) cases, respectively. Lymph node metastasis was identified in 49 patients (73.1%). Pathological stage III was the most common stage, occurring in 28 (41.8%) patients. Most procedures were performed through a transabdominal approach, reflecting the predominance of Siewert type II and III. The median number of harvested lymph nodes was 34 (21, 43) nodes per patient. There were 11 patients who had less than 15 lymph nodes retrieved.

Survival outcomes according to tumor characteristics and treatment factors are presented in Table 2. The median follow-up time was 26 (10-75) months. Poorly differentiated or undifferentiated tumors showed a trend toward worse survival compared with well- or moderately differentiated tumors; however, the difference did not reach statistical significance. Pathological T stage alone

was not significantly associated with overall survival. In contrast, pathological N stage demonstrated a strong association with survival, with progressively shorter survival observed as nodal stage increased from N0 to N3. Lymphovascular invasion was strongly associated with poorer survival, whereas perineural invasion was not. Resection status remained clinically important, with R1 resection associated with substantially worse survival than R0 resections. Neoadjuvant therapy was not significantly associated with survival outcomes, whereas patients who received adjuvant treatment had shorter survival than those who did not.

Since an LNR cut-off value of 0.2 provided the clearest separation between lower- and higher-risk groups, survival analyses were performed using this threshold. Kaplan-Meier analysis demonstrated early and sustained separation of the three LNR groups throughout the follow-up period. Patients with LNR≥0.2 exhibited the poorest survival, those with 0<LNR<0.2 had intermediate outcomes, and those with LNR=0 had the most favorable survival (p<0.001) as shown in Fig 1. In a subgroup analysis restricted to patients undergoing upfront surgery (n=58), the survival difference among the three LNR groups remained significant (p<0.001). Patients with LNR ≥0.2 continued to have significantly poorer overall survival (unadjusted HR 6.23, 95% CI 2.23–17.39, p<0.001). Cox regression analyses of factors associated with overall survival are shown in Table 3. On univariate analysis, pathological N stage was associated with a progressive increase in mortality risk, particularly among patients with N2 and N3 disease. Lymphovascular invasion, R1 resection category, adjuvant therapy, and higher LNR were also significantly associated with poorer survival outcomes. Among all evaluated variables, LNR demonstrated the strongest prognostic significance, with patients with LNR≥0.2 having the highest risk of mortality compared with those in the LNR=0 group (HR 6.21, 95%CI 2.27–17.00, p<0.001). Upon multivariate analysis, only R1 resection and LNR≥0.2 were retained in the final model.

Analysis of metastatic lymph node distribution demonstrated that nodal metastasis was concentrated primarily in the perigastric and celiac-axis regions. The highest proportion of positive nodes was observed at station 1 (25.37%). Most nodal spread occurred along the paracardial and lesser-curvature regions of the stomach. Mediastinal lymph node metastasis was less prevalent in this cohort (Fig 2). The distribution of lymph node metastases stratified by Siewert subtype is in Table 4.


TABLE 1. Clinicopathological characteristics of patients with adenocarcinoma of the esophagogastric junction.



Siewert I

Siewert II

Siewert III

P-value

(n=3)

(n=46)

(n=18)


Sex (male) (%)

2 (66.7)

32 (69.6)

11 (61.1)

0.811

Age (years)

67.7 ± 2.6

65.5 ± 12.9

61.6 + 15.3

0.537

ASA





1-2

3 (100)

37 (80.4)

13 (72.2)


3-4

0 (0)

9 (19.6)

5 (27.8)

0.507

Pathological T stage




0.319

T1

1 (33.3)

6 (13.0)

1 (5.6)


T2

1 (33.3)

9 (19.6)

2 (11.1)


T3

1 (33.3)

22 (47.8)

7 (38.9)


T4

0 (0)

9 (19.6)

8 (44.4)


Pathological N stage




0.613

N0

1 (33.3)

12 (26.1)

5 (27.8)


N1

1 (33.3)

11 (23.9)

6 (33.3)


N2

1 (33.3)

6 (13.0)

4 (22.2)


N3

0 (0)

17 (37.0)

3 (16.7)


Pathological stage




0.330

I

1 (33.3)

11 (23.9)

1 (5.6)


II

0 (0)

2 (4.3)

2 (11.1)


III

2 (66.7)

16 (34.8)

10 (55.6)


IVa

0 (0)

17 (37)

5 (27.8)


Lymphovascular invasion

0

26 (56.5%)

10 (55.6%)

0.161

Perineural invasion

1 (33.3%)

35 (76.1%)

15 (83.3%)

0.171

Total harvested lymph nodes

34 (4, 34)

33.5 (19.8, 45.3)

37 (24, 42)

0.700

Neoadjuvant therapy




0.007

Chemotherapy

2 (66.7)

4 (8.7)

0 (0)


Concurrent chemoradiation

0 (0)

2 (4.3)

1 (5.6)


Operative approach




0.360

Transthoracic

1 (33.3)

16 (34.8)

3 (16.7)


Transabdominal

2 (66.7)

30 (65.2)

15 (83.3)


Extent of surgery




0.146

Subtotal esophagectomy

2 (66.7)

15 (32.6)

1 (5.6)


Proximal gastrectomy

0 (0)

3 (6.5)

2 (11.1)


Extended gastrectomy

1 (33.3)

25 (54.3)

15 (83.3)


Transhiatal esophagectomy

0 (0)

3 (6.5)

0 (0)


R1 resection

0 (0)

6 (13.0)

1 (5.6)

0.867

Postoperative complication




0.136

Clavien-Dindo I-II

0 (0)

18 (39.1)

5 (27.8)


Clavien-Dindo III-IV

2 (66.7)

8 (17.4)

2 (11.1)


Adjuvant therapy

1 (33.3)

27 (58.7)

8 (44.4)

0.453

Data are presented as n (%), mean ± standard deviation, or median (P25, P75) where appropriate

Abbreviations: ASA = American Society of Anesthesiologists; R1 = resection category 1


TABLE 2. Survival rates stratified by tumor characteristics.



N (%)

Median OS

3-year OS

5-year OS

P-value

Differentiation





0.106

Well + moderately

41 (61.2)

52 (15.7 – 88.3)

53.7%

41.5%


Poorly

26 (38.8)

15 (0 – 31.9)

26.9%

19.2%


Pathological T stage





0.309

T1-2

20 (29.9)

63 (0 – 131.7)

65.0%

50.0%


T3-4

47 (70.1)

22 (11.6 – 32.4)

34.0%

25.5%


Pathological N stage





0.001

N0

18 (25.4)

155 (not estimable)

70.6%

58.8%


N1

18 (26.9)

37 (0 – 86.3)

44.4%

33.3%


N2

11 (16.4)

15 (0 – 44.1)

36.4%

18.2%


N3

20 (29.9)

9 (2.4 – 15.6)

25.0%

20.0%


LVI





<0.001

Negative

31 (46.3)

155 (61.6 – 248.4)

61.3%

51.6%


Positive

36 (53.7)

15 (7.9 – 22.1)

27.8%

16.7%


Perineural invasion





0.247

Negative

16 (23.9)

77 (21.4 – 132.6)

50.0%

43.8%


Positive

51 (76.1)

25 (10.1 – 39.9)

41.2%

29.4%


Resection category





0.009

R0

60 (89.6)

37 (6.9 – 67.0)

46.7%

35.0%


R1

7 (10.4)

6 (3.4 – 8.6)

14.3%

14.3%


Neoadjuvant





0.326

No

58 (86.6)

37 (8.6 – 65.5 )

46.6%

37.9%


Yes

9 (13.4)

22 (13.2 – 30.8)

22.2%

0.0%


Adjuvant treatment





0.026

No

31 (46.3)

63 (7.9 – 118.1)

51.6%

38.7%


Yes

36 (53.7)

15 (7.9 – 22.1)

36.1%

28.7%


Lymph node ratio





<0.001

LNR = 0

18 (26.9)

155 (not estimable)

68.8%

62.5%


0 < LNR < 0.2

27 (40.3)

36 (20.9 – 51.1)

50.0%

32.1%


LNR ≥ 0.2

22 (32.8)

11 (5.3 – 16.8)

18.2%

13.6%




Median overall survival is reported in months, with 95% confidence interval in the parentheses. P-values were calculated by the log-rank test.

Abbreviations: OS = overall survival; LVI = lymphovascular invasion; LNR = lymph node ratio


Fig 1. Kaplan-Meier survival curves according to lymph node ratio (LNR) group.


TABLE 3. Cox regression analysis of factors associated with overall survival.


Variable

Univariate HR (95% CI)


P-value

Multivariate* Adjusted HR (95% CI)


P-value

Poorly differentiation

1.65 (0.89-3.06)

0.112



Pathological T3-T4 stage

1.40 (0.73-2.71)

0.315



Pathological N stage N1


1.95 (0.71-5.38)


0.198



N2

3.28 (1.13-9.58)

0.030



N3

5.31 (2.08-13.61)

<0.001



Lymphovascular invasion

3.11 (1.60-6.06)

0.001



Perineural invasion

1.57 (0.72-3.40)

0.254



Resection category

3.03 (1.28-7.14)

0.014

2.78 (1.16-6.93)

0.028

Neoadjuvant therapy

1.55 (0.64-3.75)

0.334



Adjuvant therapy

2.02 (1.07-3.80)

0.030



Lymph node ratio

0 < LNR < 0.2


2.71 (1.00-7.32)


0.049


2.35 (0.86-6.46)


0.097

LNR ≥ 0.2

6.21 (2.27-17.00)

<0.001

5.90 (2.14-16.25)

0.001

*Forward stepwise selection

Abbreviations: HR = hazard ratio; CI = confidence interval; LNR = lymph node ratio

Fig 2. Distribution of metastatic lymph nodes.

Colors indicate the frequency of metastatic lymph node involvement by station. Yellow represents high-incidence nodal metastasis (>10%), green indicates intermediate incidence (5–10%), and pink represents low-incidence metastasis (0–5%). Percentages shown within each station correspond to the proportion of metastatic lymph nodes identified at that station.


TABLE 4. Distribution of metastatic lymph node stations according to Siewert classification.


Lymph node station

Siewert I (n=3)

Siewert II (n=46)

Siewert III (n=18)

Total (n=67)

1

0

15 (32.61)

2 (11.11)

17 (25.37)

2

2 (66.67)

8 (17.39)

1 (5.56)

11 (16.42)

3

1 (33.33)

11 (23.91)

2 (11.11)

14 (20.90)

4

0

2 (4.35)

0

2 (2.99)

5

0

0

1 (5.56)

1 (1.49)

6

0

3 (6.52)

0

3 (4.48)

7

1 (33.33)

9 (19.57)

4 (22.22)

14 (20.90)

8a

1 (33.33)

4 (8.70)

1 (5.56)

6 (8.96)

9

0

8 (17.39)

3 (16.67)

11 (16.42)

10

0

2 (4.35)

0

2 (2.99)

11

0

5 (10.87)

0

5 (7.46)

12a

0

1 (2.17)

0

1 (1.49)

13

0

0

0

0

14v

0

0

0

0

16

0

0

0

0

19

0

1 (2.17)

0

1 (1.49)

20

0

2 (4.35)

0

2 (2.99)

101

0

0

0

0

102

0

0

0

0

104

0

0

0

0

105

0

0

0

0

106

0

1 (2.17)

0

1 (1.49)

107

0

0

0

0

108

0

1 (2.17)

0

1 (1.49)

109

0

0

0

0

110

0

3 (6.52)

0

3 (4.48)

111

0

3 (6.52)

0

3 (4.48)

112

0

0

0

0

Data are presented as n (%), where n represents the number of metastatic lymph nodes identified at each nodal station. Percentages were calculated using the total number of patients in each Siewert subgroup as the denominator.

DISCUSSION

Lymph node metastasis remains one of the most important prognostic factors in AEG, particularly because of the complex and multidirectional lymphatic drainage pattern at the EGJ.22,23 In the current AJCC staging system, nodal status is classified according to the absolute number of metastatic lymph nodes. However, this approach may be influenced by the extent of lymphadenectomy and the total number of harvested nodes. In technically demanding tumors such as AEG, the adequacy of nodal retrieval may vary according to the operative approach, tumor location, prior neoadjuvant treatment, and pathological processing. Therefore, the LNR, which incorporates both the number of metastatic and harvested lymph nodes, has been increasingly recognized as a more stable prognostic indicator.10 One potential advantage of LNR over conventional pathological N staging is its ability to account for variability in lymph node yield. As N staging relies on the absolute number of metastatic nodes, differences in the extent of lymphadenectomy, pathological evaluation, or treatment-related reductions in nodal yield may contribute to stage migration. By incorporating both metastatic and examined lymph nodes, LNR may provide more consistent prognostic stratification across patients with varying lymph node yields.14 Several previous studies have demonstrated that LNR may provide superior prognostic discrimination compared with conventional nodal staging alone.24 Qin et al. demonstrated that an LNR≥0.2 was significantly associated with poorer overall and disease-free survival.25 This cut-off was identical to the optimal prognostic threshold identified in our cohort, further supporting its clinical relevance and reproducibility across different patient populations. Importantly, our study also characterized station-based lymph node metastasis patterns in Thai patients with AEG. The observed nodal distribution provides descriptive regional data on lymphatic spread in this cohort; however, these findings should not be interpreted as defining the optimal extent of lymphadenectomy.

Similar to previous studies, most patients in our cohort were male and presented with advanced-stage disease at diagnosis.26,27 Pathological stage III represented the largest subgroup, reflecting the aggressive biological behavior and delayed presentation commonly observed in AEG. The median number of harvested lymph nodes in the present study was relatively high at 34 nodes, exceeding the minimum threshold recommended by current guidelines. This adequate nodal yield strengthens the reliability of both pathological staging and LNR analysis. Patients with N3 disease had particularly poor survival outcomes, emphasizing the adverse prognostic impact of extensive

nodal metastasis. Lymphovascular invasion was also significantly associated with worse survival, consistent with previous studies demonstrating its association with aggressive tumor biology and systemic dissemination.28,29 Similarly, R1 resection was associated with unfavorable outcomes, in line with previous reports demonstrating the adverse impact of microscopic residual disease in AEG.30 The observed association between adjuvant therapy and poorer survival should be interpreted with caution and likely reflects confounding by indication, as patients with higher-risk disease were more likely to receive postoperative treatment, rather than an adverse effect of adjuvant therapy itself. Although poorly differentiated tumors and advanced T stage tended to be associated with inferior survival, these outcomes did not reach statistical significance, likely because of the limited sample size. Kaplan–Meier survival analysis demonstrated significant differences among the three LNR groups. Patients with LNR≥0.2 had markedly worse long-term outcomes. Furthermore, Cox regression analysis demonstrated that LNR≥0.2 had the strongest prognostic effect among the evaluated variables, with an adjusted hazard ratio indicating an approximately six-fold increase in mortality risk. These findings are consistent with previous reports demonstrating that increasing LNR is independently associated with poorer survival in patients with AEG.9,15 Beyond its prognostic value, LNR may also help identify patients at higher risk who may warrant closer postoperative surveillance and consideration of appropriate systemic therapy. However, the clinical utility of LNR for guiding postoperative management requires further prospective validation.

Regarding the distribution of lymph node metastases, our study demonstrated that nodal spread occurred predominantly in the perigastric and celiac-axis stations, particularly stations 1, 3, 7, and 9, whereas mediastinal nodal metastasis was relatively uncommon. These findings are consistent with previous mapping studies reporting that paracardial and lesser-curvature nodes are among the most frequent metastatic stations in Siewert II tumors.7,31 This pattern likely reflects the predominance of Siewert II and III tumors treated through a transabdominal approach in this cohort. Collectively, these findings support the concept that lymphadenectomy strategies for AEG should be individualized according to tumor location and expected metastatic pathways. Moreover, because evidence regarding nodal mapping in Southeast Asian populations remains scarce, our results contribute valuable regional data that may help inform future surgical strategies and the optimal extent of lymphadenectomy in this population.

Several limitations of this study should be noted. First, this was a retrospective single-center study with a relatively small sample size, which may limit statistical power and generalizability. Accordingly, the multivariable Cox analysis should be considered exploratory, and the findings require validation in a larger cohort. The low number of Siewert type I tumors in this cohort also limited subgroup comparisons according to tumor subtype. Therefore, the station-specific lymph node distribution according to Siewert classification was primarily considered descriptive, and further comparative analyses should be explored in larger cohorts with adequate representation of each subtype. Second, treatment strategies evolved during the extended study period, particularly with respect to neoadjuvant therapy and perioperative management, which may have introduced treatment-related variability over time. Over this 17-year period, advances in surgical techniques, perioperative care, pathological evaluation, and systemic treatment may have contributed to temporal heterogeneity within the cohort. Such changes could potentially influence both treatment outcomes and survival independently of the prognostic factors evaluated in this study. Additionally, the small number of patients who received neoadjuvant treatment limited further subgroup analyses regarding the treatment-specific prognostic value of LNR. As this study focused on overall survival as the primary survival endpoint, complete recurrence data were not consistently available throughout the extended study period, precluding a reliable analysis of disease-free survival. Future studies incorporating recurrence outcomes may further clarify the prognostic value of LNR. Despite these limitations, the present study remains one of the few studies evaluating both prognostic significance of LNR and station-based lymph node mapping specifically in Thai patients with AEG. Future prospective multicenter or nationwide collaborative studies may help better define metastatic nodal patterns according to Siewert subtype and guide individualized lymphadenectomy strategies.


CONCLUSION

LNR is a valuable prognostic indicator in patients with AEG and may provide improved risk stratification compared with conventional nodal staging alone. Patients with an LNR≥0.2 demonstrated significantly worse overall survival following curative-intent surgery.

Data Availability Statement

The data from this study are available upon reasonable request.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge Miss Chorlada Kertrungarun and Miss Manlika Unkam for their assistance with data collection, and Dr. Saowalak Hunnangkul for her assistance with statistical analysis.

DECLARATIONS

Grants and Funding Information

This research received no external funding.

Conflict of Interest

The authors have no conflicts of interest to declare.

Registration Number of Clinical Trial

This study does not require registration in the clinical trial as it is a retrospective study.

Author Contributions

Conceptualization and methodology, all authors ; Investigation, T.P., S.P. ; Formal analysis T.P., S.P., C.N. ; Visualization and writing – original draft, all authors; Writing - review and editing, all authors; Supervision, all authors. All authors have read and agreed to the final version of the manuscript.

Use of Artificial Intelligence

The authors used AI to support language editing and improve the clarity of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Siriraj Institutional Review Board (COA no. Si 522/2022).

Informed Consent Statement

This study was conducted following ethical and data protection regulations. Due to the retrospective nature of this study, written informed consent to participate was not obtained from study patients.

REFERENCES

  1. Takeuchi H, Kitagawa Y. Adenocarcinoma of the esophagogastric junction: territory of the esophagus or stomach, or an independent region? Ann Surg Oncol. 2013;20(3):705-6.

  2. Deans C, Yeo MSW, Soe MY, Shabbir A, Ti TK, So JBY. Cancer of the Gastric Cardia is Rising in Incidence in an Asian Population and is Associated with Adverse Outcome. World Journal of Surgery. 2011;35(3):2014.

  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

  4. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85(11):1457-9.

  5. Zhou Z, Xie X, Hao N, Diao D, Song Y, Xia P, et al. Different lymph node staging systems for patients with adenocarcinoma of esophagogastric junction. Curr Med Res Opin. 2018;34(6): 963-70.

  6. Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2. Esophagus. 2023;20(3):373-89.

  7. Kurokawa Y, Takeuchi H, Doki Y, Mine S, Terashima M, Yasuda T, et al. Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study. Ann Surg. 2021;274(1):120-7.

  8. Liang R, Bi X, Fan D, Du Q, Wang R, Zhao B. Mapping of lymph node dissection determined by the epicenter location and tumor extension for esophagogastric junction carcinoma. Front Oncol. 2022;12:913960.

  9. Melis M, Masi A, Pinna A, Cohen S, Hatzaras I, Berman R, et al. Does lymph node ratio affect prognosis in gastroesophageal cancer? Am J Surg. 2015;210(3):443-50.

  10. Zhang H, Wang W, Diao D, Cheng Y, Song Y, Zhu K, et al. Ratio of metastatic to examined lymph nodes, a helpful staging system and independent prognostic factor of esophagogastric junction cancer. PLoS One. 2013;8(8):e73238.

  11. Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119-30.

  12. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992-1004.

  13. Ajani JA, D'Amico TA, Bentrem DJ, Chakrabarti S, Corvera CU, Das P. Esophageal and Esophagogastric Junction Cancers. NCCN Clinical Practice Guidelines in Oncology. 2026;2.

  14. Kamiya H, Komatsu S, Nishibeppu K, Ohashi T, Konishi H, Shiozaki A, et al. Evaluating prognostic value and stage migration effects using a positive lymph node ratio in adenocarcinoma of the esophagogastric junction. BMC Cancer. 2023;23(1):218.

  15. Xu J, Cao J, Wang L, Wang Z, Wang Y, Wu Y, et al. Prognostic performance of three lymph node staging schemes for patients with Siewert type II adenocarcinoma of esophagogastric junction. Sci Rep. 2017;7(1):10123.

  16. Booka E, Takeuchi H, Sakai Y, Haneda R, Soneda W, Murakami T, et al. Impact of Dissected Lymph Node Count and Positive Lymph Node Ratio Following Esophagectomy on Long-Term Outcomes in Esophageal Cancer: A Systematic Review and Meta-Analysis. Ann Surg Open. 2025;6(2):e587.

  17. Song J, Zhang H, Jian J, Chen H, Zhu X, Xie J, et al. The Prognostic Significance of Lymph Node Ratio for Esophageal Cancer: A Meta-Analysis. J Surg Res. 2023;292:53-64.

  18. Jannasch O, Schwanz M, Otto R, Mik M, Lippert H, Mroczkowski

    P. Lymph Node Yield and Lymph Node Ratio for Prognosis of Long-Term Survival in Gastric Carcinoma. Cancers (Basel). 2025;17(3).

  19. Zhu J, Xue Z, Zhang S, Guo X, Zhai L, Shang S, et al. Integrated

    analysis of the prognostic role of the lymph node ratio in node-positive gastric cancer: A meta-analysis. Int J Surg. 2018;57: 76-83.

  20. Jiang Q, Zeng X, Zhang C, Yang M, Fan J, Mao G, et al. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World J Surg Oncol. 2022;20(1):261.

  21. Nampoolsuksan C, Parakonthun T, Swangsri J, Methasate A. Optimal lymph node ratio prognostic cutoff value for recurrence in gastric cancer: a cohort study. International Journal of Surgery Open. 2026;64(1):14-8.

  22. Dresner SM, Lamb PJ, Bennett MK, Hayes N, Griffin SM. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery. 2001;129(1):103-9.

  23. van de Ven C, De Leyn P, Coosemans W, Van Raemdonck D, Lerut T. Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction. Eur J Cardiothorac Surg. 1999;15(6): 769-73.

  24. Zhang Y, Liu D, Zeng D, Chen C. Lymph Node Ratio Is an Independent Prognostic Factor for Patients with Siewert Type II Adenocarcinoma of Esophagogastric Junction: Results from a 10-Year Follow-up Study. Journal of Gastrointestinal Cancer. 2021;52(3):983-92.

  25. Qin X, Gao Z, Tian L, Wang Z, Chen G, Song H, et al. Prognostic significance of lymph node ratio in adenocarcinoma of the esophagogastric junction: a study of patients after radical gastrectomy. World J Surg Oncol. 2025;24(1):59.

  26. Bai J-G, Lv Y, Dang C-X. Adenocarcinoma of the Esophagogastric Junction in China According to Siewert’s Classification. Japanese Journal of Clinical Oncology. 2006;36(6):364-7.

  27. Agarwal S, Bell MG, Dhaliwal L, Codipilly DC, Dierkhising RA, Lansing R, et al. Population Based Time Trends in the Epidemiology and Mortality of Gastroesophageal Junction and Esophageal Adenocarcinoma. Dig Dis Sci. 2024;69(1):246-53.

  28. Liu X, Jiang Q, Yue C, Wang Q. Clinicopathological Characteristics and Survival Predictions for Adenocarcinoma of the Esophagogastric Junction: A SEER Population-Based Retrospective Study. Int J Gen Med. 2021;14:10303-14.

  29. Jomrich G, Yan W, Kollmann D, Kristo I, Fallmann B, Puhr H, et al. Lymphovascular Invasion (LVI) Correlates with Systemic Immune-Inflammation Index (SII) in Adenocarcinoma of the Gastroesophageal Junction (AEG): Implications for Prognostic Stratification. Cancers. 2025;17(16):2604.

  30. Nampoolsuksan C, Bhocksombud K, Parakonthun T, Suwatthanarak T, Tawantanakorn T, Srisuworanan N, et al. Outcomes of Microscopic Residual Tumor after Curative-Intent Surgery in Adenocarcinoma of Esophagogastric Junction. Siriraj Med

    J. 2024;76(11):758-65.

  31. Fujitani K, Miyashiro I, Mikata S, Tamura S, Imamura H, Hara J, et al. Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study. Gastric Cancer. 2013;16(3):301-8.